Bordetella pertussis protein pertactin induces type-specific antibodies: One possible explanation for the emergence of antigenic variants?

Journal of Infectious Diseases

Volumn 187, Issue 8, 2003, Pages 1200-1205

  He, Qiushui ^a,c   Mäkinen, Johanna ^a   Berbers, Guy ^b   Mooi, Frits R ^b   Viljanen, Matti K ^a   Arvilommi, Heikki ^a   Mertsola, Jussi ^a  

^a UNIVERSITY OF TURKU   (Finland)

^b NATIONAL INSTITUTE FOR PUBLIC HEALTH AND THE ENVIRONMENT   (Netherlands)

^c NATIONAL PUBLIC HEALTH INSTITUTE   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIAL DNA; BACTERIUM ANTIBODY; DIPHTHERIA PERTUSSIS TETANUS VACCINE; IMMUNOGLOBULIN G ANTIBODY; MONOCLONAL ANTIBODY; PERTACTIN;

ADOLESCENT; ADULT; AMINO ACID SEQUENCE; ANTIBODY PRODUCTION; ANTIGENIC VARIATION; ARTICLE; BACTERIUM CULTURE; BORDETELLA PARAPERTUSSIS; BORDETELLA PERTUSSIS; CHILD; CONFORMATIONAL TRANSITION; CONTROLLED STUDY; DNA SEQUENCE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FINLAND; HUMAN; MAJOR CLINICAL STUDY; MALE; NONHUMAN; PERTUSSIS; PRIORITY JOURNAL; SERUM; VACCINATION;

ADOLESCENT; AMINO ACID SEQUENCE; ANTIBODIES, BACTERIAL; ANTIBODY SPECIFICITY; ANTIGENIC VARIATION; ANTIGENS, BACTERIAL; BACTERIAL OUTER MEMBRANE PROTEINS; BORDETELLA PERTUSSIS; DIPHTHERIA-TETANUS-PERTUSSIS VACCINE; FEMALE; GENES, BACTERIAL; HUMANS; INFANT; MALE; VIRULENCE FACTORS, BORDETELLA;

EID: 0344406156     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/368412     Document Type: Article

References (27)

1. Kerr JR, Matthews RR. Bordetella pertussis infection: pathogenesis, diagnosis, management, and the role of protective immunity. Eur J Clin Microbiol Infect Dis 2000; 19:77-88.
2. Bass JW, Wittler RR. Return of epidemic pertussis in the United States. Pediatr Infect Dis J 1994; 13:343-5.
3. De Serres G, Boulianne N, Douville-Fradet M, Duval B. Pertussis in Quebec: ongoing epidemic since the late 1980s. Can Commun Dis Rep 1995; 21:45-8.
4. Andrews R, Herceg A, Roberts C. Pertussis notifications in Australia, 1991 to 1997. Commun Dis Intell 1997; 21:145-8.
5. DeMelker HE, Conyn-van Spaendonck MA, Rumke HC, van Wijngaarden JK, Mooi FR, Schellekens JF. Pertussis in the Netherlands: an outbreak despite high levels of immunization with whole cell vaccine. Emerg Infect Dis 1997; 3:175-8.
6. Mooi FR, van Oirschot H, Heuvelman K, van der Heide HG, Gaastra W, Willems RJ. Polymorphism in the Bordetella pertussis virulence factors P.69/pertactin and pertussis toxin in the Netherlands: temporal trends and evidence for vaccine-driven evolution. Infect Immun 1998; 66:670-5.
7. Mooi FR, He Q, van Oirschot H, Mertsola J. Variation in the Bordetella pertussis virulence factors pertussis toxin and pertactin in vaccine strains and clinical isolates in Finland. Infect Immun 1999; 67:3133-4.
8. Mastrantonio P, Spigaglia P, van Oirschot H, et al. Antigenic variants in Bordetella pertussis strains isolated from vaccinated and unvaccinated children. Microbiology 1999; 145:2069-75.
9. Cassiday P, Sanden G, Heuvelman K, Mooi F, Bisgard KM, Popovic T. Polymorphism in Bordetella pertussis pertactin and pertussis toxin virulence factors in the United States, 1935-1999. J Infect Dis 2000; 182:1402-8.
10. Fry NK, Neal S, Harrison TG, Miller E, Matthews R, George RC. Genotypic variation in the Bordetella pertussis virulence factors pertactin and pertussis toxin in historical and recent clinical isolates in the United Kingdom. Infect Immun 2001; 69:5520-8.
11. Charles IG, Li JL, Roberts M, et al. Identification and characterization of a protective immunodominant B cell epitopes of pertactin (P.69) from Bordetella pertussis. Eur J Immunol 1991; 21:1147-53.
12. Mooi FR, Hallander H, Wirsing von König CH, Guiso N. Epidemiological typing of Bordetella pertussis isolates: recommendations for a standard methodology. Eur J Clin Microbiol Infect Dis 2000; 19:174-81.
13. Leininger E, Roberts M, Kenimer IG, et al. Pertactin, an Arg-Gly-Asp-containing Bordetella pertussis surface protein that promotes adherence of mammalian cells. Proc Natl Acad Sci USA 1991; 88:345-9.
14. Boursaux-Eude C, Thiberge S, Carletti G, Guiso N. Intranasal murine model of Bordetella pertussis infection: II. Sequence variation and protection induced by a tricomponent acellular vaccine. Vaccine 1999; 17:2651-60.
15. Cherry JD, Gornbein J, Heininger U, Stehr K. A search for serologic correlates of immunity to Bordetella pertussis cough illnesses. Vaccine 1998; 16:1901-6.
16. Storsaeter J, Hallander HO, Gustafsson L, Olin P. Levels of anti-pertussis antibodies related to protection after household exposure to Bordetella pertussis. Vaccine 1998; 16:1907-16.
17. Brennan MJ, Li ZM, Cowell JL, et al. Identification of a 69-kilodalton nonfimbrial protein as an agglutinogen of Bordetella pertussis. Infect Immun 1988; 56:3189-95.
18. Shahin RD, Brennan MJ, Li ZM, Meade BD, Manclark CR. Characterization of the protective capacity and immunogenicity of the 69-kD outer membrane protein of Bordetella pertussis. J Exp Med 1990; 171:63-73.
19. He Q, Schmidt-Schläpfer G, Just M, et al. Impact of polymerase chain reaction on clinical pertussis research: Finnish and Swiss experiences. J Infect Dis 1996; 174:1288-95.
20. Edelman K, Malmström K, He Q, Savolainen J, Terho EO, Mertsola J. Local reactions and IgE antibodies to pertussis toxin after acellular diphtheria-tetanus-pertussis immunization. Eur J Pediatr 1999; 158:989-94.
21. Tran Minh NN, He Q, Ramalho A, et al. Acellular vaccines containing reduced quantities of pertussis antigens as a booster in adolescents. Pediatrics 1999; 104:e70.
22. He Q, Viljanen MK, Ölander R-M, et al. Antibodies to filamentous hemagglutinin of Bordetella pertussis and protection against whooping cough in schoolchildren. J Infect Dis 1994; 170:705-8.
23. Tran Minh NN, He Q, Edelman K, et al. Cell-mediated immune responses to antigens of Bordetella pertussis and protection against pertussis in school children. Pediatr Infect Dis J 1999; 18:366-70.
24. King AJ, Berbers G, van Oirschot HFLM, Hoogerhout P, Knipping K, Mooi FR. Role of the polymorphic region 1 of the Bordetella pertussis protein pertactin in immunity. Microbiology 2001; 147:2885-95.
25. Emsley P, Charles IG, Fairweather NF, Isaacs NW. Structure of Bordetella pertussis virulence factors P.69 pertactin. Nature 1996; 381:90-2.
26. Boursaux-Eude C, Guiso N. Polymorphism of repeated regions of pertactin in Bordetella pertussis, Bordetella parapertussis, and Bordetella bronchiseptica. Infect Immun 2000; 68:4815-7.
27. Tozzi AE, Anemona A, Stefanelli P, et al. Reactogenicity and immunogenicity at preschool age of a booster dose of two three-component diphtheria-tetanus-acellular pertussis vaccines in children primed in infancy with acellular vaccines. Pediatrics 2001; 107:e25.